Department of Biotechnology, Microbiology and Human Nutrition, University of Life Sciences in Lublin, Lublin, Poland.
Expert Rev Neurother. 2020 Mar;20(3):271-279. doi: 10.1080/14737175.2020.1719069. Epub 2020 Jan 27.
: Alzheimer's Disease (AD) is a progressive neurodegenerative pathology characterized by the presence of neuritic plaques and neurofibrillary tangles. The most important markers in AD pathology include excessive accumulation of amyloid beta (Aβ) and phosphorylated tau (P-tau) proteins. One of the possible therapeutic strategies entails the elimination of such deposits by inhibiting Aβ aggregation. For years, one of the major problems in the treatment of AD has been the limited ability to deliver drugs to the brain for reasons related to poor solubility, low bioavailability, and the impact of the blood-brain barrier (BBB).: In recent years, the authors have observed an increasing scientific interest in nanotechnological solutions as the factors potentially capable of facilitating the treatment of neurodegenerative diseases. The authors discuss recent reports regarding the use of nanotechnology in the therapy and treatment of AD.: The current advances in nanotechnology promise a chance to overcome the obstacles posed by said limitations. The size and diversity of nanoparticles in terms of both composition and shape create new possibilities for a variety of therapeutic applications, also in the context of the treatment and diagnostics of neurodegenerative diseases, for instance in combination with magnetic resonance imaging.
阿尔茨海默病(AD)是一种进行性神经退行性病变,其特征是存在神经纤维缠结和神经原纤维缠结。AD 病变中最重要的标志物包括淀粉样β(Aβ)和磷酸化 tau(P-tau)蛋白的过度积累。一种可能的治疗策略是通过抑制 Aβ聚集来消除这些沉积物。多年来,AD 治疗的主要问题之一是由于溶解度低、生物利用度低以及血脑屏障(BBB)的影响,将药物递送到大脑的能力有限。
近年来,作者观察到科学界对纳米技术解决方案的兴趣日益增加,因为这些因素有可能促进神经退行性疾病的治疗。作者讨论了关于纳米技术在 AD 治疗和治疗中的应用的最新报告。
纳米技术的最新进展有望克服这些限制带来的障碍。纳米颗粒的大小和多样性,无论是在组成还是形状方面,都为各种治疗应用创造了新的可能性,在神经退行性疾病的治疗和诊断方面也是如此,例如与磁共振成像相结合。